Tonix Pharmaceuticals (NASDAQ:TNXP) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $12.88 and traded as high as $13.48. Tonix Pharmaceuticals shares last traded at $13.16, with a volume of 362,252 shares changing hands.

Tonix Pharmaceuticals News Summary

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: Tonix appointed Englese as chief commercial officer to help expand the reach of TONMYA, a move that could strengthen the company’s commercialization and launch efforts. Tonix Names Englese Chief Commercial Officer To Expand TONMYA Reach
• Positive Sentiment: The stock recently moved above its 200-day moving average, a technical signal that can attract momentum-focused investors and suggest improving near-term trend strength. Tonix Pharmaceuticals Share Price Passes Above 200-Day Moving Average
• Positive Sentiment: Zacks Research raised its estimates for third-quarter 2026, fourth-quarter 2026 and full-year 2026 results, implying smaller expected losses. Its FY2028 forecast also increased to positive earnings of $1.86 per share from $1.67.
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. The figures provide no evidence of meaningful short-covering or elevated bearish positioning and may reflect incomplete data.
• Negative Sentiment: Zacks lowered its FY2027 earnings forecast to a loss of $5.48 per share from a loss of $4.10, highlighting continued uncertainty about the company’s path to profitability despite improved 2026 and 2028 estimates.

Analyst Upgrades and Downgrades

TNXP has been the subject of several analyst reports. Wall Street Zen upgraded Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings cut Tonix Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $27.00 price target on shares of Tonix Pharmaceuticals in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $24.50.

Tonix Pharmaceuticals Trading Down 4.3%

The stock has a market capitalization of $210.60 million, a P/E ratio of -0.95 and a beta of 1.74. The firm’s fifty day moving average is $12.13 and its 200-day moving average is $12.87.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Monday, August 10th. The company reported ($2.44) earnings per share for the quarter, topping the consensus estimate of ($2.64) by $0.20. Tonix Pharmaceuticals had a negative net margin of 548.64% and a negative return on equity of 68.99%. The firm had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $7.72 million. Equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -10.03 EPS for the current year.

Insider Buying and Selling

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average cost of $13.79 per share, for a total transaction of $27,580.00. Following the transaction, the chief executive officer directly owned 11,005 shares in the company, valued at approximately $151,758.95. The trade was a 22.21% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders purchased 4,415 shares of company stock worth $55,108. 2.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Tonix Pharmaceuticals by 238.1% in the third quarter. Vanguard Group Inc. now owns 556,957 shares of the company’s stock worth $13,456,000 after purchasing an additional 392,225 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at $2,895,000. Geode Capital Management LLC increased its stake in shares of Tonix Pharmaceuticals by 182.4% in the second quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock valued at $6,305,000 after buying an additional 113,175 shares in the last quarter. Nuveen LLC raised its holdings in shares of Tonix Pharmaceuticals by 507.7% in the fourth quarter. Nuveen LLC now owns 93,402 shares of the company’s stock valued at $1,459,000 after buying an additional 78,033 shares during the last quarter. Finally, Capital Fund Management S.A. bought a new position in shares of Tonix Pharmaceuticals in the third quarter valued at about $1,521,000. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.